Dyne Therapeutics (DYN) Debt Ratio (2020 - 2026)
Dyne Therapeutics (DYN) posted quarterly Debt Ratio of 0.2 for Q2 2026, up 47.94% year-over-year from 0.14 in Q2 2025, and up 44.98% quarter-over-quarter from 0.14 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Debt Ratio (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Debt Ratio for 3 consecutive years, with 0.2 the latest figure, recorded in Q2 2026.
- In Q2 2026, Debt Ratio rose 47.94% year-over-year to 0.2; the TTM figure through Jun 2026 stood at 0.2 (up 47.94% YoY), while the FY2025 annual figure was 0.18, changed N/A from the prior year.
- Debt Ratio improved to 0.2 in Q2 2026 per DYN's latest filing, from 0.14 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.2 in Q2 2026 and bottomed at 0.11 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 0.47 |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 0.26 |
| 10 | Dyne Therapeutics | 4.01 Bn | 4.01 Bn | - | 0.20 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.20 |
| Mar 31, 2026 | 0.14 |
| Dec 31, 2025 | 0.18 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | 0.14 |
| Sep 30, 2020 | 0.03 |